Blood Res.  2014 Mar;49(1):61-64. 10.5045/br.2014.49.1.61.

A case of oxaliplatin-induced immune-mediated thrombocytopenia

• Suh SE
• Jang MJ
• Chong SY
• Aster RH
• Curtis BR
• Oh D

• KMID: 2172825
• DOI: http://doi.org/10.5045/br.2014.49.1.61

Abstract

Oxaliplatin is a platinum compound used in patients with gastrointestinal malignancies. It is known to evoke a drug-induced immune-mediated thrombocytopenia, which has not been reported in Korea. We describe a 53-year-old man who developed oxaliplatin-induced immune-mediated thrombocytopenia during chemotherapy for colon cancer. Oxaliplatin-dependent IgG platelet antibodies were detected in his serum on flow cytometry. He was treated with immunoglobulin and corticosteroids without any complications. Physicians should consider oxaliplatin-induced immune-mediated thrombocytopenia, when a sudden, isolated thrombocytopenia develops during chemotherapy with oxaliplatin.

Keyword

Oxaliplatin; Thrombocytopenia; Immune; Drug-dependent platelet antibody

MeSH Terms

Adrenal Cortex Hormones
Antibodies
Blood Platelets
Colonic Neoplasms
Drug Therapy
Flow Cytometry
Humans
Immunoglobulin G
Immunoglobulins
Korea
Middle Aged
Platinum
Thrombocytopenia*
Adrenal Cortex Hormones
Antibodies
Immunoglobulin G
Immunoglobulins
Platinum

Figure

• 

  Fig. 1 Clinical course of the patient.

• 

  Fig. 2 Detection of oxaliplatin-dependent platelet antibodies by using flow cytometry. Patient's serum, but not normal serum, reacted with group O platelets in the presence of oxaliplatin 0.1 mg/mL (black histograms) but not in its absence (gray). No reactions were obtained with fluorouracil (5-FU) or leucovorin (not shown). Numbers shown above for each histogram represent the median fluorescence intensity (MFI) values, in log scale.

Reference

1. Jardim DL, Rodrigues CA, Novis YA, Rocha VG, Hoff PM. Oxaliplatin-related thrombocytopenia. Ann Oncol. 2012; 23:1937–1942. PMID: 22534771.

2. Taleghani BM, Meyer O, Fontana S, et al. Oxaliplatin-induced immune pancytopenia. Transfusion. 2005; 45:704–708. PMID: 15847658.

3. Curtis BR, Kaliszewski J, Marques MB, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol. 2006; 81:193–198. PMID: 16493620.

4. Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010; 28:2549–2555. PMID: 20406923.

5. Desrame J, Broustet H, Darodes de Tailly P, Girard D, Saissy JM. Oxaliplatin-induced haemolytic anaemia. Lancet. 1999; 354:1179–1180. PMID: 10513718.

6. Earle CC, Chen WY, Ryan DP, Mayer RJ. Oxaliplatin-induced Evan's syndrome. Br J Cancer. 2001; 84:441. PMID: 11161414.

7. Dahabreh I, Tsoutsos G, Tseligas D, Janinis D. Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol. 2006; 6:5. PMID: 16968538.

8. Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol. 2010; 3:12. PMID: 20346128.

9. Edmondson DA, Gruling BJ, Urmanski AM, Wong SJ, Levy MB. Oxaliplatin hypersensitivity: case report and successful repeat desensitization. Am J Ther. 2007; 14:116–118. PMID: 17303980.